ANIP
ANIP
US00182C1036
ANI Pharmaceuticals, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 72/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±45.5% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.5x).

Beta (Market Relation)
0.5x
Defensive
Volatility (5Y p.a.)
45.5% p.a.
5-Year Horizon
Max Drawdown (5Y)
-59.4%
5-Year Horizon
Sharpe Ratio
0.26
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -21.5%
3 Years 36.1% -29.0% 0.14 +7.4%
5 Years 45.5% -59.4% 0.26 +14.1%
10 Years 48.0% -73.0% -0.04 +0.5%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (45.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -73.0% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
1 ISS Score: 1 / 10
Audit Risk
6 ISS Score: 6 / 10
Board Risk
1 ISS Score: 1 / 10
Short Ratio
7.01
ende